Overview

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Antithrombin III
Antithrombins